These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 19175937)

  • 1. Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay.
    Knight LA; Kurbacher CM; Glaysher S; Fernando A; Reichelt R; Dexel S; Reinhold U; Cree IA
    BMC Cancer; 2009 Jan; 9():38. PubMed ID: 19175937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay.
    Knight LA; Conroy M; Fernando A; Polak M; Kurbacher CM; Cree IA
    Anticancer Drugs; 2005 Oct; 16(9):969-76. PubMed ID: 16162973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents.
    Budman DR; Calabro A
    Oncology; 2006; 70(2):147-53. PubMed ID: 16645328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay.
    Fehm T; Zwirner M; Wallwiener D; Seeger H; Neubauer H
    BMC Cancer; 2012 Jul; 12():308. PubMed ID: 22824103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiated suppression of Dickkopf-1 in breast cancer by combined administration of the mevalonate pathway inhibitors zoledronic acid and statins.
    Göbel A; Browne AJ; Thiele S; Rauner M; Hofbauer LC; Rachner TD
    Breast Cancer Res Treat; 2015 Dec; 154(3):623-31. PubMed ID: 26515701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma.
    Baulch-Brown C; Molloy TJ; Yeh SL; Ma D; Spencer A
    Leuk Res; 2007 Mar; 31(3):341-52. PubMed ID: 16996129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic Antiproliferative Effects of Zoledronic Acid and Fluvastatin on Human Pancreatic Cancer Cell Lines: An in Vitro Study.
    Elsayed M; Kobayashi D; Kubota T; Matsunaga N; Murata R; Yoshizawa Y; Watanabe N; Matsuura T; Tsurudome Y; Ogino T; Ohdo S; Shimazoe T
    Biol Pharm Bull; 2016 Aug; 39(8):1238-46. PubMed ID: 27181081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined inhibition of the mevalonate pathway with statins and zoledronic acid potentiates their anti-tumor effects in human breast cancer cells.
    Göbel A; Thiele S; Browne AJ; Rauner M; Zinna VM; Hofbauer LC; Rachner TD
    Cancer Lett; 2016 May; 375(1):162-171. PubMed ID: 26968247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer.
    Göbel A; Zinna VM; Dell'Endice S; Jaschke N; Kuhlmann JD; Wimberger P; Rachner TD
    BMC Cancer; 2020 Jul; 20(1):703. PubMed ID: 32727400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells.
    Goard CA; Chan-Seng-Yue M; Mullen PJ; Quiroga AD; Wasylishen AR; Clendening JW; Sendorek DH; Haider S; Lehner R; Boutros PC; Penn LZ
    Breast Cancer Res Treat; 2014 Jan; 143(2):301-12. PubMed ID: 24337703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the mevalonate pathway augments the activity of pitavastatin against ovarian cancer cells.
    Abdullah MI; Abed MN; Richardson A
    Sci Rep; 2017 Aug; 7(1):8090. PubMed ID: 28808351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.
    Jagdev SP; Coleman RE; Shipman CM; Rostami-H A; Croucher PI
    Br J Cancer; 2001 Apr; 84(8):1126-34. PubMed ID: 11308265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal women.
    Thompson K; Keech F; McLernon DJ; Vinod K; May RJ; Simpson WG; Rogers MJ; Reid DM
    Bone; 2011 Jul; 49(1):140-5. PubMed ID: 21047568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxicity of the new antimetabolite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay.
    Schott S; Wallwiener M; Kootz B; Seeger H; Fehm T; Neubauer H
    Invest New Drugs; 2012 Aug; 30(4):1750-5. PubMed ID: 21604021
    [No Abstract]   [Full Text] [Related]  

  • 15. [-Chemosensitivity testing in gynecologic oncology. Experiences with an ATP bioluminescence assay-].
    Kurbacher CM; Mallmann P; Kurbacher JA; Hübner H; Krebs D
    Geburtshilfe Frauenheilkd; 1996 Feb; 56(2):70-8. PubMed ID: 8647362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VEGFA Involves in the Use of Fluvastatin and Zoledronate Against Breast Cancer.
    Pu H; Zhang Q; Zhao C; Shi L; Wang Y; Wang J; Zhang M
    Pathol Oncol Res; 2018 Jul; 24(3):557-565. PubMed ID: 28744693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mevalonate pathway intermediates downregulate zoledronic acid-induced isopentenyl pyrophosphate and ATP analog formation in human breast cancer cells.
    Räikkönen J; Mönkkönen H; Auriola S; Mönkkönen J
    Biochem Pharmacol; 2010 Mar; 79(5):777-83. PubMed ID: 19819230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
    Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
    Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statin-induced inhibition of breast cancer proliferation and invasion involves attenuation of iron transport: intermediacy of nitric oxide and antioxidant defence mechanisms.
    Kanugula AK; Gollavilli PN; Vasamsetti SB; Karnewar S; Gopoju R; Ummanni R; Kotamraju S
    FEBS J; 2014 Aug; 281(16):3719-38. PubMed ID: 24964743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells.
    Taylor-Harding B; Orsulic S; Karlan BY; Li AJ
    Gynecol Oncol; 2010 Dec; 119(3):549-56. PubMed ID: 20837358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.